The Aim of this independent, parallel, twelve-week clinical study is to assess the efficacy of a commercially available oxygenated mouth rinse and mouth foam on both plaque level and gingival status in addition to assessing the oral health related quality of life.

Start Date01 Oct 2023

Sponsor / Collaborator

King's College London

[+1]

NCT04693715

/ CompletedPhase 2

RESCUE: A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

A Phase II, randomized, blinded, placebo-controlled, parallel group study with patients experiencing a large vessel occlusion acute ischemic stroke who are selected for endovascular revascularization. Participants will be given a 48 h infusion of either 0.5 mL/kg/h RNS60 (up to a maximum of 60 mL/h), 1 mL/kg/h RNS60 (up to a maximum of 120 mL/h), or 1 mL/kg/h (up to a maximum of 120 mL/h) placebo (normal saline) starting within 30 minutes of consent after confirmation of candidacy for endovascular thrombectomy.

Start Date07 Jul 2021

Sponsor / Collaborator

Revalesio Corp.

100 Clinical Results associated with RNS-60

100 Translational Medicine associated with RNS-60

100 Patents (Medical) associated with RNS-60

Literatures (Medical) associated with RNS-60

01 Sep 2025·STROKE

Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke

Article

Author: Clark, Wayne M. ; McTaggart, Ryan A. ; Smith, Wendy ; Cook, Douglas J. ; Ghosh, Supurna ; Ansari, Sameer A. ; Dubow, Jordan S. ; Madsen, Tracy E. ; Kalmes, Andreas ; Chiu, David ; Moldovan, Krisztina ; Sutherland, Jocelyn ; Mock, Jarrad ; Liebeskind, David S. ; Favilla, Christopher G. ; Fisher, Marc ; Jayaraman, Mahesh ; Torabi, Radmehr

BACKGROUND::

Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE (A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic.

METHODS::

This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale.

RESULTS::

The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3]; P <0.05). No statistically significant differences were observed in other efficacy end points, but a higher proportion of participants in the RNS60 1.0 mL/kg per hour group had reduced disability (modified Rankin Scale score of 0–2) and functional independence (Barthel Index ≥95) on Day 90.

CONCLUSIONS::

RNS60 was safe and well tolerated. The RNS60 1.0 mL/kg per hour reduced infarct growth after endovascular thrombectomy compared with placebo. This suggests a benefit warranting investigation in a larger, appropriately powered trial.

REGISTRATION::

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04693715.

01 Jul 2025·MUSCLE & NERVE

An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis

Article

Author: Yu, Hong ; Rohrer, Margot ; Babu, Suma ; Gelevski, Dario ; Paganoni, Sabrina ; D'Agostino, Derek ; Cudkowicz, Merit ; McCormack, Mary ; Luppino, Sarah ; Berry, James ; Leite, Alex ; Locatelli, Matteo ; Kalmes, Andreas ; Weiss Sadan, Anat ; Mock, Jarrad ; Parikh, Neil ; Scirocco, Erica ; Addy, Grace ; Neel, Dylan V. ; Giacomelli, Elisa ; Roderick, Aimee ; Scalia, Jennifer ; Sherman, Alexander V.

ABSTRACT:

Aims:

RNS60 is an investigational product in clinical development for amyotrophic lateral sclerosis (ALS). RNS60 slowed disease progression in the ALS SOD1G93A mouse model and was safe and well tolerated both in an open‐label pilot study and a randomized, placebo‐controlled, multicenter phase 2 trial in people living with ALS. The objective of this ongoing expanded access protocol (EAP) was to provide RNS60 to people living with ALS who are ineligible for controlled clinical trials and to collect data on the safety and tolerability of dosing RNS60 via twice‐daily nebulization rather than the previously studied daily nebulization with weekly intravenous administration.

Methods:

Eligible participants (≥ 18 years old, diagnosed with ALS per investigator assessment, and ineligible for an ALS clinical trial testing RNS60) were treated with twice‐daily nebulization of RNS60 at home. Safety was evaluated by the assessment of adverse events and routine safety labs.

Results:

A total of 84 participants have been treated with RNS60 via nebulization twice daily for up to 48 months so far. The most common treatment‐related adverse event was increased secretions [N = 27 (32%)]. Serious adverse events (SAEs) [69 occurrences; N = 38 (45%) with at least one SAE] and deaths [N = 24 (28%)] were deemed not related to RNS60.

Discussion:

This EAP supports the benign side effect profile of RNS60 when administered via twice‐daily nebulization and demonstrates the feasibility of long‐term EAPs as a complementary approach to controlled trials in people with advanced ALS.

01 Nov 2024·BRAIN BEHAVIOR AND IMMUNITY

Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis

Article

BACKGROUND:

Positive effects of RNS60 on respiratory and bulbar function were observed in a phase 2 randomized, placebo-controlled trial in people with amyotrophic lateral sclerosis (ALS).

OBJECTIVE:

to investigate the long-term survival of trial participants and its association with respiratory status and biomarkers of neurodegeneration and inflammation.

STUDY DESIGN AND SETTINGS:

A randomized, double blind, phase 2 clinical trial was conducted. Trial participants were enrolled at 22 Italian Expert ALS Centres from May 2017 to January 2020. Vital status of all participants was ascertained thirty-three months after the trial's last patient last visit (LPLV). Participants were patients with Amyotrophic Lateral Sclerosis, classified as slow or fast progressors based on forced vital capacity (FVC) slope during trial treatment. Demographic, clinical, and biomarker levels and their association with survival were also evaluated.

RESULTS:

Mean duration of follow-up was 2.8 years. Long-term median survival was six months longer in the RNS60 group (p = 0.0519). Baseline FVC, and rates of FVC decline during the first 4 weeks of trial participation, were balanced between the active and placebo treatment arms. After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group. Rates of FVC progression during the treatment were strongly associated with long-term survival (median survival: 3.7 years in slow FVC progressors; 1.6 years in fast FVC progressors). The effect of RNS60 in prolonging long-term survival was higher in participants with low neurofilament light chain (NfL) (median survival: >4 years in low NfL - RNS60 group; 3.3 years in low NfL - placebo group; 1.9 years in high NfL - RNS60 group; 1.8 years in high NfL - placebo group) and Monocyte Chemoattractant Protein-1 (MCP-1) (median survival: 3.7 years in low MCP-1 - RNS60 group; 2.3 years in low MCP-1 - placebo group; 2.8 years in high MCP-1 - RNS60 group; 2.6 years in high MCP-1 - placebo group) levels at baseline.

CONCLUSIONS AND RELEVANCE:

In this post-hoc analysis, long term survival was longer in participants randomized to RNS60 compared with those randomized to placebo and was correlated with slower FVC progression rates, suggesting that longer survival may be mediated by the drug's effect on respiratory function. In these post-hoc analyses, the beneficial effect of RNS60 on survival was most pronounced in participants with low NfL and MCP-1 levels at study entry, suggesting that this could be a subgroup to target in future studies investigating the effects of RNS60 on survival.

TRIAL REGISTRATION:

Study preregistered on 13/Jan/2017 in EUDRA-CT (2016-002382-62). The study was also registered at ClinicalTrials.gov number NCT03456882.

News (Medical) associated with RNS-60

31 Jul 2025

·www.prnewswire.com

Revalesio Receives FDA Fast Track Designation for RNS60 for the Treatment of Acute Ischemic Stroke

TACOMA, Wash., July 31, 2025 /PRNewswire/ -- Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced that the U.S. Food and Drug Administration has granted Fast Track designation to RNS60, its lead investigational therapy, for the treatment of acute ischemic stroke. This designation is intended to accelerate the development and review of RNS60, which could fill a major gap in stroke care by protecting brain tissue even after blood flow is restored with standard procedures and medications. Stroke is a leading cause of long-term disability and the second leading cause of death worldwide.i While advances in endovascular thrombectomy have improved outcomes for some patients, a large percentage continue to experience permanent neurological deficits due to brain tissue damage sustained even after blood flow is restored. No FDA-approved therapies currently exist to protect the brain during or after reperfusion. RNS60 is an oxygen-supersaturated saline intended to support mitochondria activity, increase cellular resilience, modulate inflammation and protect at-risk brain tissue following ischemic injury. Revalesio is currently preparing to initiate RESTORE, a Phase 3 trial that will evaluate the safety and efficacy of RNS60 in a broader population of stroke patients eligible for endovascular therapy. The Fast Track designation was granted based on the Phase 2 RESCUE trial and a supportive preclinical data package. "The Fast Track designation underscores the urgent need for new treatments that go beyond restoring blood flow to actually protect brain tissue and preserve neurological function," said Dr. Jordan Dubow, Chief Medical Officer of Revalesio. "We believe RNS60 represents a fundamentally different approach to stroke care, and this designation reinforces the importance of advancing it as quickly as possible." About FDA Fast Track Designation The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies that treat serious or life-threatening conditions and have the potential to address unmet medical needs. Programs granted Fast Track designation benefit from more frequent interactions with the FDA, eligibility for Accelerated Approval and Priority Review, and the option to submit a New Drug Application on a rolling basis. About RNS60 RNS60 is a proprietary, oxygen-enriched saline with demonstrated cytoprotective, anti-inflammatory, and mitochondrial-supportive properties. The treatment is being developed as an adjunctive therapy for acute ischemic stroke and in other neurological conditions, such as ALS and Alzheimer's Disease. The company is preparing to launch a Phase 3 clinical trial of RNS60 in acute ischemic stroke based on promising Phase 2 data showing reduced brain tissue loss, improved functional outcomes, and shorter hospital stays in patients treated within 24 hours of stroke onset. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in fluid physics, modulates fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. Media: Lori Murray [email protected] i Feigin VL, Stark BA, Johnson CO, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis. Lancet Neurol. 2021 Oct;20(10):795–820. doi: 10.1016/S1474-4422(21)00252-0 SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Fast Track

21 Jul 2025

·www.prnewswire.com

Revalesio Announces Publication of RESCUE Phase 2 Trial Results Evaluating RNS60 as an Adjunctive Therapy for Acute Ischemic Stroke in the Journal Stroke

Trial met primary endpoints of similar rates of serious adverse events (SAEs) and fewer deaths observed with RNS60 versus placebo Statistically significant reduction in infarct growth (brain tissue loss) – a secondary endpoint – in patients treated with RNS60 adjunct to endovascular thrombectomy Results support advancement of RNS60 to Phase 3 TACOMA, Wash., July 21, 2025 /PRNewswire/ -- Revalesio, a clinical-stage biopharmaceutical company developing treatments for acute and chronic neurological disorders, today announced the peer-reviewed publication of results from its RESCUE Phase 2 clinical trial evaluating RNS60 as an adjunctive treatment in patients with acute ischemic stroke. The paper, titled "Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke," appears in the journal Stroke. RESCUE is the first randomized, double-blind, placebo-controlled clinical trial to evaluate RNS60 in patients (n=82) with large vessel occlusion, or blockage in one of the brain's main arteries, undergoing endovascular thrombectomy (EVT), a standard of care procedure to remove blood clots from the brain. RNS60 is a proprietary, oxygen-supersaturated saline formulation intended to support mitochondria, increase cellular resilience and modulate inflammation following ischemic injury. The RESCUE trial met its primary endpoints of similar rates of SAEs (33.3%, 25.0% and 28.6%) and fewer deaths (6.7%, 8.3% and 14.3%) across RNS60 0.5 mL/kg/h, RNS60 1.0 mL/kg/h, and placebo, respectively. RNS60 also demonstrated a statistically significant 47% reduction in infarct growth (brain tissue loss) – a secondary endpoint – at 48 hours in patients treated with RNS60 at 1.0 mL/kg/h compared to placebo (p<0.05). "Stroke remains the number one cause of disability worldwide, resulting in a substantial global economic burden. The ability to safely deliver a cytoprotective treatment adjunct to EVT would be transformative," said Marc Fisher, M.D., Neurologist Beth Israel Deaconess Medical Center, Harvard Medical School, and former World Stroke Organization President. "The RESCUE trial lays the foundation for a new treatment paradigm in stroke care, where more patients may benefit from effective intervention beyond the narrow window of traditional reperfusion therapies." Revalesio is preparing to launch the RESTORE study, a Phase 3 clinical trial evaluating RNS60 at 1.0 mL/kg/h in a broader population of stroke patients. "The publication of these results in a respected peer-reviewed journal underscores the strength of our Phase 2 proof of concept data and highlights the urgent need for new treatment options in acute ischemic stroke," said Jordan Dubow, M.D., Chief Medical Officer at Revalesio. "We are preparing to launch our Phase 3 RESTORE trial to evaluate RNS60 in a larger population and move closer to delivering a meaningful new option for stroke patients." About RNS60 RNS60 is a proprietary, oxygen-enriched saline with demonstrated cytoprotective, anti-inflammatory, and mitochondrial-supportive properties. The treatment is being developed as an adjunctive therapy for acute ischemic stroke and in other neurological conditions, such as ALS and Alzheimer's Disease. The company is preparing to launch a Phase 3 clinical trial of RNS60 in acute ischemic stroke based on promising Phase 2 data showing reduced brain tissue loss, improved functional outcomes, and shorter hospital stays in patients treated within 24 hours of stroke onset. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in fluid physics, modulates fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media: Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical ResultPhase 3

21 May 2025

·www.prnewswire.com

Revalesio Presents Additional Analyses from the Phase 2 RESCUE Clinical Trial for RNS60 in Acute Ischemic Stroke

TACOMA, Wash., May 21, 2025 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced data from a post hoc analysis of its completed Phase 2 RESCUE clinical trial, showing that ischemic stroke patients treated with 1.0 mL/kg/h RNS60 plus standard of care endovascular thrombectomy (EVT) within 12 hours of stroke onset showed a larger numerical benefit compared to placebo than the overall group treated within 24 hours. Of note, patients from this subgroup (approximately 75% of the trial participants) experienced a reduction in infarct volume growth (brain tissue loss) post-EVT by more than 50% (nominal p<0.05) and were discharged from the hospital on average 4.8 days sooner (nominal p=0.022) than patients who received EVT and a placebo. These results were presented today during a poster session at the European Stroke Organisation Conference being held in Helsinki, Finland from May 21-23, 2025. "These data suggest RNS60 could change the trajectory of stroke recovery," said Bert van den Bergh, Revalesio's Executive Chairman of the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. "By preserving brain tissue and reducing the need for long hospital stays or long-term care, we have the opportunity to fundamentally reshape post-stroke care." Poster Presentation Highlights from the poster presentation for the post-hoc subgroup of subjects who were randomized within 12 hours of LKW and received 1.0 mL/kg/h of RNS60: Reduction in infarct growth of 50% (p<0.05) Discharged 4.8 days sooner from the hospital (p=0.022) 72% of subjects were independent compared to 37% on placebo based on dichotomized modified Rankin Scale (0-2) at Day 90 (p=0.13) RNS60 was generally safe and well tolerated in the overall intent to treat population "There's an urgent need for therapies that do more than restore blood flow—these data suggest RNS60 may protect the brain itself," said Greg Archambeau, President of Revalesio and co-inventor of RNS60. "These results support advancing RNS60 into a pivotal Phase 3 trial, with the goal of delivering a meaningful new standard of care." About the RESCUE Phase 2 Clinical Trial In RESCUE, a multi-center, double-blinded, placebo-controlled, randomized Phase 2 clinical trial, Revalesio evaluated the safety and initial efficacy of RNS60. Eighty-two participants with AIS eligible for endovascular thrombectomy (EVT) were enrolled and received intravenous RNS60 0.5 mL/kg/h (low dose), RNS60 1.0 mL/kg/h (high dose), or placebo starting before completion of the EVT and continuing for 48 hours. The trial had two primary endpoints: safety and mortality. Secondary endpoints for the study evaluated disability based on the well-established modified Rankin Scale (mRS), change in the size of the stroke as measured by MRI at 48 hours, and additional endpoints including Barthel Index, NIHSS, and EQ-5D-5L). About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media: Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2

100 Deals associated with RNS-60

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	-	Revalesio Corp.	01 Oct 2026
Acute Ischemic Stroke	Phase 2	United States	Revalesio Corp.	07 Jul 2021
Asthma	Phase 2	United Kingdom	Revalesio Corp.	01 Apr 2015
Lacerations	Phase 2	United States	Revalesio Corp.	09 Dec 2013
Pain, Postoperative	Phase 2	United States	Revalesio Corp.	09 Dec 2013
Multiple Sclerosis, Relapsing-Remitting	Phase 2	United States	Revalesio Corp.	25 Oct 2012
Pain	Phase 1	United Kingdom	Revalesio Corp.	01 Jul 2015
Myocardial Infarction	Phase 1	United States	Revalesio Corp.	01 Jul 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04693715 (RESCUE, Pubmed \| Stroke)	Phase 2	Acute Ischemic Stroke	82	RNS60 0.5 mL/kg per hour	qauzldbica(uyifmfyqbn) = rveyyfdpnj erxobefgrl (jdmupffujl ) View more	Positive	01 Sep 2025
				RNS60 1.0 mL/kg per hour	qauzldbica(uyifmfyqbn) = htokjyjwpg erxobefgrl (jdmupffujl ) View more
RESCUE (AAN2025)	Phase 2	Acute Ischemic Stroke	82	RNS60 1 mL/kg/h	towrpzwzgl(peoacopbwh) = twoonrothg kpkfgbzpmr (vmrfsplexr )	Positive	07 Apr 2025
				Placebo 1 mL/kg/h	towrpzwzgl(peoacopbwh) = yidelkvzbe kpkfgbzpmr (vmrfsplexr )
NCT04693715 (RESCUE, PRNewswire) Manual	Phase 2	Acute Ischemic Stroke	-	RNS60 1.0 mL/kg/h (high dose)	jognnizoca(ubogtfjlzh) = nfhpauowfb hcnhjmhoyi (gcllvqgnto ) View more	Positive	05 Feb 2025
				RNS60 0.5 mL/kg/h (low dose)	-
EUCTR2016-002382-62-IT \| NCT03456882 (Pubmed \| Brain Behav Immun)	Phase 2	Amyotrophic Lateral Sclerosis forced vital capacity (FVC) slope \| neurofilament light chain (NfL) \| Monocyte Chemoattractant Protein-1 (MCP-1)	-	RNS60	rksuggnkfr(zvqhcxgmat) = After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group hoeplvotre (ijcxfnmuyh ) View more	Positive	01 Nov 2024
				Placebo
NCT03456882 (RNS60 \| ###DELETE \| EUDRA-CT (2016-002382-62), CTgov)	Phase 2	Amyotrophic Lateral Sclerosis	147	RNS60 (RNS60)	ibqciaydwd(temdessvsw) = owhtdwdnuu faffzlwppm (dplvklqpqw, 1.8) View more	-	21 Apr 2023
				RNS60 (NORMAL SALINE)	ibqciaydwd(temdessvsw) = ibzaudfmsn faffzlwppm (dplvklqpqw, 1.9) View more
NCT02525471 (CTgov)	Phase 1	Amyotrophic Lateral Sclerosis	24	RNS60	mpjmyallwv = drvoqjsyuy xhcumpvpet (zcvnsisljc, zzbjzwwwuu - uzjusjvtan) View more	-	03 Mar 2021
Nano Cl iv (ECTRIMS2019)	Phase 2	Clinically isolated syndrome \| Multiple Sclerosis, Relapsing-Remitting	36	RNS60	mtmexiusoo(spjwyxnbsw) = kulaqtietm fukmewkmir (dneyeboyry, 0.42 - 1.06)	Positive	10 Sep 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RNS-60

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation